KCT0005884尚未招募未知
T2 low (non-allergic/non-acid composition) drug therapy optimization of mild asthma prospective clinical study
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 304
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 18(Year) 至 80(Year)(—)
- 性别
- All
入选标准
- •1) Adult asthma patients between the ages of 18 and 80 years old
- •2) Definition of patients with mild asthma (GINA steps 1 to 2)
- •Absolute Criteria: Blood eosinophil less than 300 & allergen check
- •(skin tests 14 or more or MAST tests) All negative
- •FENO (less than 25) or sputum eosinophil (less than 3%) in patients who meet the above absolute criteria.
- •Register if one is satisfied
- •- The above criteria are applied the same when reassessing the washout visibility after 6 months.
- •3) For more than three months, use low dose ICS only, LRTA only, or prn Ventolin without worsening asthma.
- •The T2 low criteria above are tested after a month of drug interruption in a stable patient.
- •a satisfied patient
- •4) New asthma-diagnosed mild case
- •5) FEV1 (%) > 80
排除标准
- •1) Minors under the age of 18 and older than 80 years of age;
- •2) Smoking power of 10PY or higher or current smokers
- •3) In case of acute deterioration of steroid injection above 30 mg prednisolone was required within 6 months prior to registration of the study;
- •4) In addition to severe asthma, severe respiratory diseases are accompanied by clinically significant respiratory diseases
- •5) In case it is difficult to evaluate asthma alone due to severe respiratory diseases (Lung canner, Tb destroyed Lung, Interstitial Lung disease, etc.)
- •6) Hypereosinophilic syndrome, ABPA, EGPA, COPD
- •7) Pregnant women
- •8) Patients who are unable to use LAMA drugs due to side effects
- •£ Benign prostatic hypertrophy (BPH) in severe cases
- •£ New disease
研究者
相似试验
进行中(未招募)
1 期
Phase II Study of IMP321 plus pembrolizumab in non-small cell lung cancer (NSCLC) or head and neck cancer (HNSCC)EUCTR2018-001994-25-PLImmutep S.A.S.183
进行中(未招募)
不适用
THERAPEUTIC SIMPLIFICATION WITH THYMIDINE ANALOGUR SPARING REGIMENS IN PATIENTS ON EFFECTIVE HAART: A CONTROLLED, RANDOMIZED STUDYTREATMENT HIVEUCTR2005-004025-26-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)
进行中(未招募)
1 期
Treatment of diabetic macular edema and wet age-related macular degeneration in the eye with a substance suppressing a growth factor (TGF-Beta2)eovascular age-related macular degeneration (nAMD)Diabetic Macular edema (DME)MedDRA version: 20.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853MedDRA version: 20.0Level: LLTClassification code 10075568Term: Wet age-related macular degenerationSystem Organ Class: 100000004853EUCTR2021-001213-36-ATIsarna Therapeutics GmbH60
尚未招募
2 期
Phase IIa study to evaluate the efficacy of the ISTH0036 in treatment naive and previously treated patients with Macular Degeneration and Diabetic Macular EdemaCTRI/2022/04/041823Isarna Therapeutics
进行中(未招募)
1 期
Terbutaline for the treament of painful neuropathyPainful polyneuropathyMedDRA version: 18.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 100000004852EUCTR2015-002984-40-DKDepartment of Neurology, Odense University Hospital58
